Skip to content
Screener

Praxis Precision Medicines, Inc. PRAX Q2 2026 earnings

Reported August 6, 2026 · Before market open

EPS-$2.87Beat by $0.80
Revenue estimate$1.3M
EPS estimate-$3.67

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$130.8K
EPS estimate-$3.65

Financials

Q2 2026

Income statement

See full
Operating income-$96.9M-27.4%
Net income-$83.7M-17.7%
EPS (diluted)-$2.87+13.3%

Balance sheet

See full
Cash & equivalents$474.8M+201%
Total debt$1.1M+44.0%
Total equity$1.3B+232%
Total assets$1.4B+207%

Cash flow

See full
Operating cash flow-$77.5M-41.8%
CapEx$245.0K+338%
Free cash flow-$77.8M-42.1%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$8.63B+831%
Enterprise value$8.15B+959%

Returns & leverage

See full
Return on equity-38.9%-10.3pp
Debt / equity0×0.0×
Current ratio15.7×+9.4×

FAQ

When did Praxis Precision Medicines, Inc. report Q2 2026 earnings?
Praxis Precision Medicines, Inc. (PRAX) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Praxis Precision Medicines, Inc.'s Q2 2026 revenue and EPS?
Praxis Precision Medicines, Inc. reported eps of $-2.87 for Q2 2026.
Did Praxis Precision Medicines, Inc. beat estimates in Q2 2026?
EPS beat the consensus estimate of $-3.67 by $0.80.
How did Praxis Precision Medicines, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 13.3% from $-3.31.
Where can I find Praxis Precision Medicines, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001689548-26-000082) and the 10-Q periodic report (0001689548-26-000083) directly on SEC EDGAR. The filing index links above go to sec.gov.